Drugs /

lirilumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
lirilumab
NCI Definition [1]:
A fully humanized monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon administration, lirilumab binds to KIR, thereby preventing the binding of KIR ligands to KIR on natural killer (NK) cells. By blocking these inhibitory receptors, NK cells become activated and attack cancer cells leading to tumor cell death. KIR, a member of the immunoglobulin superfamily, is expressed on the surface of NK cells.

Clinical Trials

View Clinical Trials for lirilumab

Lirilumab has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating lirilumab, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open).

Bladder urothelial carcinoma, glioblastoma, and gliosarcoma are the most common diseases being investigated in lirilumab clinical trials [2].

Drug Details

Synonyms [2]:
bms-986015, lirilumab, anti-kir monoclonal antibody iph2102, iph2102
Drug Categories [2]:
Immunotherapies, Therapeutic antibodies
Drug Target(s) [2]:
KIR2DL1, KIR3DL2, KIR3DL3
NCIT ID [1]:
C103820

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.